What the trial was testing
The SURMOUNT-2 enrolled 938 patients with type 2 diabetes. The study was sponsored by Eli Lilly and Company and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
People taking tirzepatide lost up to 15% of their body weight over 72 weeks, compared to 3% with placebo.
Lancet (London, England) · 2023 · NCT04657003
These findings — that people on the higher dose lost 15% of their body weight versus 3% on placebo — were published in the Lancet (London, England) and represent the headline result of the study.
Researchers tracked outcomes across 938 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with type 2 diabetes, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Tirzepatide is FDA-approved for type 2 diabetes and weight management. It's available now under brand names including Mounjaro (for diabetes) and Zepbound (for weight management). If you have type 2 diabetes and are struggling with weight, talk to your doctor about whether tirzepatide might be right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open type 2 diabetes trials
A Participatory Approach to Support Glucose Tolerance Tracking in Real-Life of Patients With Type 2 Diabetes
Recent studies show that lifestyle interventions, such as exercise, healthy diet, and education, can help prevent type 2 diabetes in high-risk individuals, and even reverse the disease in its early stages. However, not many methods have been developed to use modern technology to help people manage their diabetes in a more active way, in line with participatory medicine, where patients play a key role in their treatment. In this study, the investigators propose an e-health approach to automatically collect health data from patients, including information from continuous glucose monitor (CGM) and other health tracking devices, in real-life conditions. The investigators will also develop a simple and easy-to-understand tool to track patient's metabolic status and will analyze how it relates to lifestyle changes using the data collected during the study. Twenty sedentary individuals with type 2 diabetes, not on insulin treatment, will take part in the trial. All patients will be monitored for two weeks using a CGM device and an activity tracker. During the first week, participants will follow their normal daily routine, while in the second week, subjects will be asked to engage in moderate physical activity every day, consisting of walking. At the end of each week, patients will take a meal tolerance test. The main goal of the study is to measure how blood sugar levels change over the two weeks, also evaluating the impact of individuals' daily activities like exercise on it. The research team will develop and use mathematical models to measure this change. A secondary goal is to evaluate the ease of use of the e-health system for data collection.
The Effect of Motivational Interviewing on Diabetes Self-Management and Severity of Cyberchondria in Individuals With Diabetes
Objective: The aim of this study was to determine the effects of diabetes education given to individuals with diabetes using motivational interviewing technique based on the health promotion model on diabetes self-management and cyberchondria severity. Materials and Method: The population of the study consisted of 1000 individuals. The sample consisted of 64 individuals, 32 experimental and 32 control, who met the research criteria. The research will be conducted between 15.02.2025-15.03.2025 in Van Regional Training and Research Hospital Diabetes outpatient clinic. Data in the research; Descriptive Information Form, Diabetes Self-Management Scale (DMS), Cyberchondria Severity Scale-Short Form (CSS-SF) scales will be applied. Research experiment Motivational interviewing intervention based on the health belief model will be conducted once a week for 1 month. At the end of 1 month, both scales will be administered again to individuals in both experimental and control groups.